Search results

He just went quiet. I think so too. But it doesn't matter. He was a part of the last guideline development group, so evidently part of the problem, but said he wouldn't do it again. And if he's not willing to speak out in the meetings, then it's unlikely to impact on the guidelines. If we can...

There is a conspicuous disconnect between what the clinics describe and what patients say is happening in the worst cases. Perhaps they really do intend to tailor treatments for everyone, and be supportive, but over the years have started rushing things and getting defensive at patient pushback...

He brought it up, but I pointed out the flaws in the trial and that they dropped objective measures (he'd previously agreed that using actometers was a sensible idea, although it seemed like the idea had never occurred to him before, which is worrying). This seemed to put an end to that, and the...

It is, but NICE clarified that doesn't mean they'll be recommended--just that they'll be included in the evidence. Jonathan also pointed out that narrative summaries of studies aren't suitable in this case, and they seemed to agree. They also agreed that the criticisms and discussions around...

Agreed. They knew the issues. There was surprisingly little to argue about. NICE even acknowledged that criticisms of existing studies would also be borne in mind.

Almost certainly.